- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00157820
DATAS: The Dual Chamber & Atrial Tachyarrhythmias Adverse Events Study (DATAS)
Study Overview
Status
Detailed Description
Single chamber (SC) implantable cardioverter defibrillators (ICDs) have several limitations that might be relevant during follow up, like atrial pacing requirements, inadequate therapies, sustained atrial tachyarrhythmias and difficulties to achieve an accurate diagnosis of the arrhythmia. Dual chamber (DC) ICDs offer an attractive rationale solution, although controversy remains if the costs and complexity of the implants offer a real clinical advantage.
The DATAS is a, prospective, multicentre, randomized, open labelled study, with three arms (two of them cross-over and the third parallels the other two)
The primary objective of this trial is to determine whether use of Dual Chamber ICD (DDED-DDDR NASPE/BPEG Defibrillator/Pacemaker Codes) results in a significant decrease in the number of primary end points.
The primary end point is a composite comprising four so-denominated "Clinically Significant Adverse Events (CSAE)":
- all-cause mortality
- invasive intervention, hospitalization (>24 h) or prolongation of hospitalization due to cardiovascular cause
- inappropriate shocks (two or more episodes with inappropriate shocks)
- sustained symptomatic atrial tachyarrhythmias that (a) require urgent termination or (b) last more than 48 h leading to therapeutic intervention.
Secondary objectives are:
- Number of each of the components of the CSAE.
- Arrhythmia related: atrial tachyarrhythmia (AT), frequency and burden, ventricular tachyarrhythmia frequency and burden number of appropriate shocks, number of inappropriate shocks, need for reprogramming, need for medication/Radiofrequency Ablation (RFA) for arrhythmia control, pacemaker syndrome and development of dual chamber pacing indication.
- Cardiovascular related: New York Health Association (NYHA) functional class, exercise capacity, left ventricular ejection fraction (LVEF), reduction of medication (diuretics.).
- Quality of life: evaluated by the SF-36, Minnesota living test, with heart failure and Symptom Checklist instruments.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Meet the Class I implantation criteria for single chamber implantable cardioverter defibrillator according to the guidelines (ACC/AHA).
Exclusion Criteria:
- Permanent atrial fibrillation
- Patients without structural heart disease
- Patient meets implantation criteria for dual-chamber pacing (symptomatic sinus node disease, all 2nd Atrio-Ventricular (AV) block [except asymptomatic Mobitz I] and all 3rd degree AV block ).
- Patient with previous system implanted (ICD or pacemaker).
- Patients with biventricular stimulation or re-synchronization.
- Patient has a mechanical right heart valve.
- Patient has medical conditions that would preclude the testing required by the protocol, or limit study participation.
- Patient is unwilling or unable to cooperate or give written informed consent, or the patient is a minor and legal guardians refuse to give informed consent.
- Patient is or will be inaccessible for follow-up at the study center.
- Patients who are enrolled or planning to enroll in other clinical trials during the clinical study.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: SC true
Single chamber Implantable Cardioverter Defibrillator programmed as a Single Chamber.
|
Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
Other Names:
|
Experimental: SC sim
Dual chamber ICD initially programmed as single chamber (SC simulated) ICD (''SC sim arm'')
|
Dual chamber ICD implantation: Jewel AF & GemIII AT as DC ICDs (DC true and SC sim arms)
Other Names:
|
Experimental: DC true
Dual chamber ICD initially programmed as a DDED (''DC true arm'').
|
Dual chamber ICD implantation: Jewel AF & GemIII AT as DC ICDs (DC true and SC sim arms)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
CSAE-score Rate(Clinical Significant Adverse Events Score Rate)
Time Frame: 17 months
|
Main outcome was defined as the CSAE-score during follow-up: CSAE-score rate.
We assigned death as the worst outcome during the entire study; and premature cross-over as the main failure of the assigned therapy.
So each CSAE was assigned 1 point but (a) death was assigned a score equal to the max number of CSAE in any individual patient in the entire study +1, and (b) premature authorized crossover was given a score equal to the max number of CSAE in any individual patient in that period.
Thus, main outcome was defined as the CSAE-score over length of follow-up resulting in a CSAE-score rate.
|
17 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Each of the Components of the CSAE
Time Frame: 17 months
|
The primary endpoint is a composite of 5 pre-determine Clinical Significant Adverse Events (CSAE): (1) all-cause mortality, (2) invasive intervention due to Cardiovascular cause, (3) hospitalization (>24h) or prolongation of hospitalization due to CV, (4) inappropriate shocks: two or more episodes with inappropriate shocks, (5) sustained symptomatic ATs that (a) require urgent termination or (b) lasted more than 48 h leading to therapeutic intervention. Number of each of the components of CSAE, counts the number of events for each pre-determined level. |
17 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Aurelio Quesada, MD, Hospital General Universitario, Valencia, Spain
- Principal Investigator: Jesus Almendral, MD, Hospital General Universitario Gregorio Marañón, Madrid, Spain
- Principal Investigator: Fernando Arribas, MD, Hospital Universitario 12 de Octubre, Madrid, Spain
- Principal Investigator: Massimo Santini, MD, San Filippo Neri Hospital, Rome, Italy
- Principal Investigator: Christian Wolpert, MD, University Hospital Mannheim, Mannheim, Germany
- Principal Investigator: Pedro Adragao, MD, Santa Cruz Hospital, Carnaxide, Portugal
Publications and helpful links
General Publications
- Quesada A, Almendral J, Arribas F, Ricci R, Wolpert C, Adragao P, Cobo E, Navarro X; DATAS Investigators. The DATAS rationale and design: a controlled, randomized trial to assess the clinical benefit of dual chamber (DDED) defibrillator. Europace. 2004 Mar;6(2):142-50. doi: 10.1016/j.eupc.2003.11.011.
- Almendral J, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A; DATAS Steering Committee; DATAS Writing Committee; DATAS Investigators. Dual-chamber defibrillators reduce clinically significant adverse events compared with single-chamber devices: results from the DATAS (Dual chamber and Atrial Tachyarrhythmias Adverse events Study) trial. Europace. 2008 May;10(5):528-35. doi: 10.1093/europace/eun072. Epub 2008 Apr 7.
- Ricci RP, Quesada A, Almendral J, Arribas F, Wolpert C, Adragao P, Zoni-Berisso M, Navarro X, DeSanto T, Grammatico A, Santini M; DATAS study Investigators. Dual-chamber implantable cardioverter defibrillators reduce clinical adverse events related to atrial fibrillation when compared with single-chamber defibrillators: a subanalysis of the DATAS trial. Europace. 2009 May;11(5):587-93. doi: 10.1093/europace/eup072.
- Hadid C, Almendral J, Ortiz M, Schwab JO, Janko S, Mischke K, Arribas F, Wolpert C, Ricci R, Adragao P, Cobo E, Navarro X, Quesada A. Incidence, determinants, and prognostic implications of true pleomorphism of ventricular tachycardia in patients with implantable cardioverter-defribillators: a substudy of the DATAS Trial. Circ Arrhythm Electrophysiol. 2011 Feb;4(1):33-42. doi: 10.1161/CIRCEP.110.957068. Epub 2010 Nov 13.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- SP-DATAS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Ventricular Fibrillation
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Enrolling by invitationShort-coupled Idiopathic Ventricular FibrillationNetherlands
-
Guidant CorporationBoston Scientific CorporationCompletedHeart Failure | Ventricular Tachycardia, Ventricular FibrillationIsrael, Denmark
-
Boston Scientific CorporationCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular TachycardiaUnited States, Netherlands
-
Biosense Webster, Inc.RecruitingVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexItaly, Croatia, Israel
-
Biosense Webster, Inc.CompletedVentricular Tachycardia | Paroxysmal Atrial Fibrillation | Persistent Atrial Fibrillation | Scar-related Atrial Tachycardia | Premature Ventricular ComplexCroatia, Belgium, Italy
-
Mayo ClinicMedtronicCompletedAtrial Fibrillation | Ventricular Fibrillation | Ventricular Tachycardia | Supraventricular TachycardiaUnited States, Israel
-
Institute for Clinical and Experimental MedicineRecruitingAtrial Fibrillation | Acute Heart Failure | Left Ventricular Dysfunction | Atrial Fibrillation RapidCzechia
-
University of Turin, ItalyUniversity of Padova; Centro Cardiologico Monzino; Policlinico Casilino ASL RMB; Humanitas Research Hospital IRCCS, Rozzano-MilanUnknownPersistent Atrial Fibrillation | Congestive Heart Failure Due to Left Ventricular Systolic Dysfunction
-
Abbott Medical DevicesCompletedVentricular Tachycardia | Persistent Atrial FibrillationCanada, South Africa, Denmark, Australia, Italy, Austria, France, Germany, Netherlands, Portugal, Spain
-
Ottawa Heart Institute Research CorporationNot yet recruitingVentricular Fibrillation | Ventricular Tachycardia | Ventricular Arrhythmias | Recurrent Ventricular Tachycardia
Clinical Trials on Single Chamber Implantable Cardioverter Defibrillator
-
Boston Scientific CorporationCompleted
-
Medtronic Cardiac Rhythm and Heart FailureMedtronicCompletedHeart DiseasesUnited States
-
Boston Scientific CorporationCompleted
-
Population Health Research InstituteBoston Scientific CorporationCompleted
-
Medtronic Bakken Research CenterAstraZenecaCompletedAcute Myocardial InfarctionNetherlands
-
Rennes University HospitalCompleted
-
Medtronic Cardiac Rhythm and Heart FailureCompletedVentricular ArrhythmiasGermany, United States, Denmark, Canada, Netherlands, Switzerland, Austria
-
Maurizio Eugenio LandolinaRecruitingAppropriate and Inappropriate Shock Therapy With ICD | Arrhythmias DetectionItaly
-
Deutsches Herzzentrum MuenchenCompleted
-
Biotronik SE & Co. KGCompletedTachyarrhythmiaGermany, Switzerland